Exactech Inc. manufactured knee replacement implants with defective packaging that lacked an inner oxygen barrier, causing polyethylene liners to degrade before implantation. The resulting premature implant failures led to a 2022 recall covering ~147,000 US patients. Lawsuits allege Exactech and parent company TPG Capital knew of the packaging defect and failed to warn surgeons and patients. The primary remedy — revision surgery — is a major operation with serious complication risks.
Litigation Timeline
TPG Capital Acquires Exactech for $737 Million
Private equity firm TPG Capital completes acquisition of Exactech Inc., a Gainesville, Florida-based orthopedic implant manufacturer, for approximately $737 million. Plaintiffs allege TPG assumed responsibility for known quality control deficiencies, including the non-conforming packaging used on PE liners, and failed to remediate the defect post-acquisition.
Exactech Initiates Voluntary Recall — Initial Scope
Exactech voluntarily initiates a recall of certain polyethylene knee, hip, and ankle replacement components with the FDA. The recall is classified as Class II (risk of adverse health consequences, though not immediately life-threatening). Initial scope covers select product lines with identified packaging non-conformance — the defective single-barrier vacuum bags lacking the required inner oxygen barrier layer.
Recall Dramatically Expanded to 147,000 US Patients
Exactech dramatically expands the voluntary recall to encompass approximately 147,000 affected devices in the United States. The expanded recall covers Optetrak, Optetrak Logic, and Truliant knee systems, plus Alteon, Novation, and Connexion hip systems and the Vantage ankle system — all PE liners packaged in non-conforming bags. The scale of the expansion triggers widespread media coverage and alerts orthopedic surgeons nationwide to identify and notify affected patients.
First Product Liability Lawsuits Filed Against Exactech and TPG Capital
Plaintiff attorneys begin filing the first wave of product liability lawsuits against Exactech Inc. and TPG Capital in state and federal courts. Initial filings are concentrated in New York state court and the Middle District of Florida. Complaints allege manufacturing defect, design defect, failure to warn, negligence, breach of implied warranty, and fraud or misrepresentation. TPG Capital is named under alter-ego and PE parent liability theories.
Case Concentration and Informal Coordination in State Courts
As the case count exceeds several hundred filings across state and federal courts, plaintiff steering committees begin organizing informal coordination of pretrial proceedings. New York state court (complex litigation part) emerges as the primary venue for coordinated discovery. The Middle District of Florida also sees significant case volume given Exactech's Gainesville headquarters. Discussions of a formal federal MDL petition are ongoing among plaintiff leadership.
Over 1,000 Cases Filed; Bellwether Selection Discussions Begin
The total case count across federal and state courts surpasses 1,000 filed claims as of Q4 2025. Plaintiff and defense counsel begin discussions regarding bellwether trial selection — a representative group of cases selected for early trial to inform the parties on litigation value and factual disputes. Expert discovery, including science days on PE oxidation science and packaging industry standards, is anticipated in 2026. First bellwether trials are projected for 2027 in the absence of a global settlement.
Notable Verdicts & Settlements
Johnson & Johnson's DePuy Orthopaedics division settled approximately 8,000 claims in the ASR hip recall MDL for a global fund exceeding $2.5 billion. Average per-claimant settlements were reported at approximately $228,000, though cases with serious complications settled for significantly more. The DePuy ASR recall is the closest comparable to the Exactech recall in terms of defective orthopedic implant causing premature failure and requiring revision surgery. This settlement is frequently cited by plaintiff attorneys as a benchmark for Exactech case values.
Stryker Corporation settled claims arising from the Rejuvenate and ABG II hip stem recalls for over $1 billion, with average per-claimant settlements reported at approximately $300,000+. The Stryker recall, like Exactech's, involved a packaging/materials defect causing premature implant failure and mandatory revision surgery. The higher average per-claim value in Stryker compared to DePuy is frequently cited by plaintiff attorneys as an upward data point for Exactech valuation.
Zimmer Biomet's Durom Cup hip implant recall resulted in individual trial verdicts ranging from $1 million to $5 million for cases with serious complications. Settled cases averaged approximately $100,000–$500,000 depending on injury severity. The Durom Cup litigation demonstrated that juries are willing to award significant damages in orthopedic device cases where manufacturer negligence is well-documented, and that cases with permanent disability or multiple revisions command verdicts in the millions.
Plaintiff attorneys have reported that a small number of individual Exactech cases have reached confidential settlements in 2024–2025, prior to any global resolution. The amounts are not publicly disclosed. These early resolutions suggest Exactech and TPG Capital are willing to resolve the strongest individual cases rather than proceed to trial in those specific matters — a common defense strategy to avoid early unfavorable verdicts that would set high precedent for global settlement negotiations.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Exactech Knee Recall Case Page